Novo Nordisk announced on June 12, 2025, its decision to advance subcutaneous and oral amycretin into phase 3 development for weight management, based on positive feedback from regulatory authorities. The phase 3 program is set to start in Q1 2026 and aims to address obesity and type 2 diabetes.